Business
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFu
About this update from Emergent Biosolutions Inc.
[{"type":"image","alt":"Emergent BioSolutions","displaySize":"","headline":null,"caption":"Emergent BioSolutions","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8Cci..ShG_us_SMdQyxhzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d","width":300,"height":36}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior year","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior year","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior year","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior year","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of 54%, an expansion of 1,900 bps and 900 bps, respectively, versus prior year","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2025 Adjusted EBITDA of $205.0 million, compares favorably to $183.1 million in 2024","length":94,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":869,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025.","length":174,"tagName":"p"},{"type":"text","content":"“Emergent’s 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved o...